Global Burden of Kidney Disease High, Inequities in Care Common Global Burden of Kidney Disease High, Inequities in Care Common
By 2030, 14.5 million people around the world will have end-stage kidney disease (ESKD), yet only 5.4 million will be treated due to economic, social and political factors. And more than 2 million people will die each year due to little or no access to hemodialysis or kidney transplantation.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news
Trial Results Unclear for Benefit of Longer Hemodialysis Sessions
THURSDAY, April 18, 2019 -- Intervention uptake was insufficient to allow evaluation of its impact in a pragmatic trial designed to assess the effect of longer hemodialysis duration on death and other outcomes; the findings from the Time to Reduce... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2019 Category: Pharmaceuticals Source Type: news
A case report of massive acetaminophen poisoning treated with a novel "triple therapy": N-acetylcysteine, 4-methylpyrazole, and hemodialysis - Kiernan EA, Fritzges JA, Henry KA, Katz KD.
Massive acetaminophen (N-acetyl-p-aminophenol; APAP) ingestion is characterized by a rapid onset of mitochondrial dysfunction, including metabolic acidosis, lactemia, and altered mental status without hepatotoxicity which may not respond to the standard do... (Source: SafetyLit)
Source: SafetyLit - April 11, 2019 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Psychoactive Medications in Older Adults on Hemodialysis Psychoactive Medications in Older Adults on Hemodialysis
Are psychoactive medications, such as sedative-hypnotics, and antidepressants with anticholinergic properties, associated with major adverse outcomes among older hemodialysis patients?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2019 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
FTC grants final approval for Fresenius ’ s $2B buyout of NxStage
The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical.
The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use during hemodialysis treatment.
To mollify the anti-trust regulators, NxStage last July agreed to deal its Medisystems bloodlines business to B. Braun.
The final order was approved in a three-to-two vote, according to an FTC posting.
The $30-per-sha...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Dialysis Featured Mergers & Acquisitions Wall Street Beat Fresenius NxStage Medical Inc. Source Type: news
Pursuit Vascular Announces CE Mark Approval for ClearGuard HD Caps
Milestone opens international markets for the company
MAPLE GROVE, Minn., April 3, 2019 -- (Healthcare Sales & Marketing Network) -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, today announced that the company... Devices, Regulatory, Product Launch Pursuit Vascular, ClearGuard, Antimicrobial Barrier, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2019 Category: Pharmaceuticals Source Type: news
Two Therapies for Treating Depression in Dialysis Patients Two Therapies for Treating Depression in Dialysis Patients
Dr Bansal describes a new study that compares CBT and sertraline for depressed patients on hemodialysis for end- stage renal disease.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 1, 2019 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news
Hemodialysis device maker Phraxis raises $6m
Early stage medical device company Phraxis has raised approximately $5.6 million in a new round of equity and options financing, according to a recently posted SEC filing.
Phraxis is developing a novel treatment for patients who need vascular access for hemodialysis, according to the company’s website.
The St. Paul, Minn.-based company’s first product for commercialization is the InterGraft, a percutaneously delivered arteriovenous shunt intended to provide a unique, non-surgical approach for patients who need vascular access, according to the site.
Money in the round came from seven unnamed investors, with the first s...
Source: Mass Device - March 21, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Phraxis Inc. Source Type: news
Fresenius Awarded Breakthrough Device Designation for Software
Fresenius Medical Care hit a significant milestone last week with its software to enhance its line of hemodialysis machines. FDA granted breakthrough device designation to the company’s computer-assisted ultrafiltration control software. The software is in development to improve fluid management during hemodialysis and personalize treatments.
Fluid management is a critical concern for dialysis patients, as both fluid overload and fluid depletion are associated with adverse cardiovascular events, morbidity and mortality. Working with the CLiC device which enables relative blood volume monitori...
Source: MDDI - March 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Fresenius wins FDA breakthrough device nod for fluid management software
Fresenius (NYSE:FMS) said yesterday that it won FDA breakthrough device designation for its computer-assisted ultrafiltration control software intended to improve fluid management during hemodialysis.
The Waltham, Mass.-based company said that the software is designed to work with its newer hemodialysis machines using its CLiC device.
Fresenius said that with the software, it hopes to create a dialysis machine with embedded intelligent diagnostics to provide computer-assisted recommendations for achieving target levels of relative blood volume.
“This new software represents our commitment to driving innovation and a...
Source: Mass Device - March 15, 2019 Category: Medical Devices Authors: Fink Densford Tags: Dialysis Featured Food & Drug Administration (FDA) Software / IT Fresenius Source Type: news
St. Paul firm pursuing easier hemodialysis treatments closes on nearly $6 million round
St. Paul-based Phraxis Inc.'s device offers an alternative to a central venous catheter. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 13, 2019 Category: American Health Authors: Alex Wittenberg Source Type: news
St. Paul firm pursuing easier hemodialysis treatments closes on nearly $6 million round
St. Paul-based Phraxis Inc.'s device offers an alternative to a central venous catheter. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 13, 2019 Category: Biotechnology Authors: Alex Wittenberg Source Type: news
Tenapanor Reduces Elevated Serum Phosphate in CKD
FRIDAY, March 8, 2019 -- For hyperphosphatemic patients with chronic kidney disease receiving maintenance hemodialysis, tenapanor significantly reduces elevated serum phosphate, according to a study published online March 7 in the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2019 Category: Pharmaceuticals Source Type: news
Cantel Medical slumps on fiscal Q2 misses
Cantel Medical (NYSE:CMD) shares took a hit this week when the medical device company missed the consensus forecast with its fiscal second-quarter results.
Little Falls, N.J.-based Cantel posted a -42.1% profit slide to $18.8 million, or 45¢ per share, on sales of $224.5 million for the three months ended Jan. 31, for top-line growth of 5.4% compared with fiscal Q2 2018.
Adjusted to exclude one-time items, earnings per share were 57¢, a nickel below the consensus on Wall Street, where analysts were looking for revenues of $226.9 million.
“We are pleased to see continued strong double-digit sales growth in our medi...
Source: Mass Device - March 1, 2019 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Cantel Medical Corp. Source Type: news
Sertraline, CBT Ease Depression in Patients on Dialysis Sertraline, CBT Ease Depression in Patients on Dialysis
Cognitive-behavioral therapy (CBT) and the selective serotonin reuptake inhibitor sertraline each eased depression among patients undergoing maintenance hemodialysis, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news
